People with advanced neuroendocrine tumors in the digestive system may benefit from a treatment combination that includes the drug Lu 177-dotatate (Lutathera), according to the results of a first-of-its-kind clinical trial.
All participants in the trial, called NETTER-2, had advanced neuroendocrine tumors in the gastrointestinal tract or pancreas that had not yet been treated.
Those who received Lu 177-dotatate plus octreotide (Sandostatin) lived almost three times as long without their cancer getting worse (progression-free survival) as those who received octreotide alone—a median of nearly 23 months, versus 8.5 months. And the number of people whose tumors shrank, sometimes completely, was nearly five times greater in those who received both drugs compared to those who only received octreotide.
Comments are closed.